EGFR and non-small cell lung carcinoma: Genetic mutations commonly found in NSCLC, such as alterations in KRAS, EGFR, anaplastic lymphoma kinase (ALK), and liver kinase B1 (LKB1), drive distinct metabolic reprogramming in tumor cells (69).